Press briefings and stakeholder meetings
HumanCOVID-19
Press briefings
EMA held press briefings to announce breaking news and explain its latest scientific work in tackling the COVID-19 pandemic:
- EMA regular press briefing on public health emergencies (06/06/2023)
- EMA regular press briefing on public health emergencies (15/02/2023)
- EMA regular press briefing on public health emergencies (16/12/2023)
- EMA regular press briefing on public health emergencies(24/11/2022)
- EMA regular press briefing on COVID-19 and monkeypox(26/10/2022)
- EMA regular press briefing on COVID-19 and monkeypox(20/09/2022)
- EMA regular press briefing on COVID-19 and monkeypox(02/09/2022)
- EMA regular press briefing on COVID-19(07/07/2022)
- EMA regular press briefing on COVID-19(02/06/2022)
- EMA regular press briefing on COVID-19(05/05/2022)
- EMA regular press briefing on COVID-19(17/03/2022)
- EMA regular press briefing on COVID-19(03/03/2022)
- EMA regular press briefing on COVID-19(17/02/2022)
- EMA regular press briefing on COVID-19(03/02/2022)
- EMA regular press briefing on COVID-19(18/01/2022)
- EMA regular press briefing on COVID-19(11/01/2022)
- EMA regular press briefing on COVID-19(21/12/2021)
- EMA regular press briefing on COVID-19(09/12/2021)
- EMA regular press briefing on COVID-19 (18/11/2021)
- EMA regular press briefing on COVID-19(04/11/2021)
- EMA regular press briefing on COVID-19(21/10/2021)
- EMA press briefing to inform on CHMP discussion on booster doses(05/10/2021)
- EMA regular press briefing on COVID-19(23/09/2021)
- EMA regular press briefing on COVID-19(09/09/2021)
- EMA regular press briefing on COVID-19(15/07/2021)
- EMA regular press briefing on COVID-19(01/07/2021)
- EMA regular press briefing on COVID-19(17/06/2021)
- EMA regular press briefing on COVID-19(28/05/2021)
- First EMA regular press briefing on COVID-19(12/05/2021)
- EMA press briefing to update on analysis of data on Vaxzevria, the COVID-19 vaccine from AstraZeneca(23/04/2021)
- Press briefing on PRAC conclusions on signal of thromboembolic events with COVID-19 Vaccine Janssen(20/04/2021)
- Press briefing on the conclusion of the assessment of the Pharmacovigilance Risk Assessment Committee (PRAC) of Vaxzevria (previously COVID-19 Vaccine AstraZeneca) and thromboembolic events(07/04/2021)
- Press briefing on the conclusion of the investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events by the Pharmacovigilance Risk Assessment Committee (PRAC)(18/03/2021)
- Press briefing on EU recommendation for COVID-19 Vaccine AstraZeneca(29/01/2021)
- Press briefing on EU recommendation on first COVID-19 vaccine(21/12/2020)
Public stakeholder meetings
EMA held public stakeholder meetings to discuss its work on the assessment, approval and safety monitoring of COVID-19 vaccines:
- Public stakeholder meeting on COVID-19 vaccines and therapeutics in the EU (25/11/2021)
- Public stakeholder meeting: approval, safety monitoring and impact of COVID-19 vaccines in the EU (26/03/2021)
- Public stakeholder meeting on the approval and roll-out of COVID-19 vaccines in the EU (08/01/2021)
- Public stakeholder meeting: development and authorisation of safe and effective COVID-19 vaccines in the EU (11/12/2020)